← Back to homepage
AstraZeneca invests £1.5bn into US firm Summit for cancer drug tie-up
Sources
3
Coverage
Limited spectrum
Sentiment
0.00
◀ Left 67%Centre 33%Right 0% ▶
How we rate bias →NewsDeck Poll
Do you think this story is being covered fairly across the political spectrum?
Loading…
Left
(2)
Evening Standard
AstraZeneca invests £1.5bn into US firm Summit for cancer drug tie-up
The firms will collaborate on Summit’s experimental new medicine as well as researching how it could be combined with Astra’s treatments.
29 Sept, 08:20
Guardian Business
Anthropic warns of ‘existential risks to humanity’ from AI; AstraZeneca makes $2bn cancer drug tie-up – business live
Rolling coverage of the latest economic and financial news
Pharmaceuticals news: AstraZeneca is investing $2bn in biopharmaceutical oncology company Summit Therapeutics, as part of a tie-up to jointly develop and test anti-cancer drugs.
Announcing the deal, AstraZeneca says the two companies will collaborate on a series of studies testing their cancer treatments together.
“A core pillar of our oncology strategy is t…
29 Sept, 06:43
Centre
(1)
City AM
Astrazeneca invests $2bn in cancer drug tie-up
Astrazeneca has invested $2bn in US pharmaceutical firm Summit Therapeutics as part of a blockbuster cancer research tie-up. The FTSE 100 drugs giant has agreed to buy 109,000 shares in Nasdaq-listed Summit for $18.36 per share as part of the deal. The tie-up will see the two pharma giants collaborate on a series of studies [...]
29 Sept, 06:36
Right
(0)
No coverage from this perspective yet